Announcements Trials
Browse Landscape

Phase

Phase 1 14Phase 2 9Phase 1/2 2Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Head & Neck 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × MLN 8237 × Clear all
NCT01397825 2018-03-27

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine

Takeda

Phase 1/2 Completed
45 enrolled 24 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT01045421 2016-08-15

Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

Millennium Pharmaceuticals, Inc.

Phase 1/2 Completed
273 enrolled 28 charts
BreastHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡